Golden Suisse Hosts Exclusive Event at Grand Hôtel Stockholm with Anders Borg
ZURICH, Dec. 19, 2024 /PRNewswire/ -- Golden Suisse, a global leader in secure wealth solutions, hosted an exclusive evening at the renowned Grand Hotel Stockholm, drawing Sweden's financial elite, private banking leaders, and High Net Worth...
Lingnan University participates in the 2024 Academy of International Business Asia Pacific Regional Conference
HONG KONG, Dec. 16, 2024 /PRNewswire/ -- The 2024 Academy of International Business (AIB) Asia Pacific Regional Conference was held from 4 to 6 December in Guangzhou. This year's conference, "Reimagine International Business: Accelerate Growth...
2024 SABCS｜Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis
YANTAI, China, Dec. 13, 2024 /PRNewswire/ -- On the morning of December 12, 2024 (UTC-6), at the Poster Spotlight Session "Novel HER2 Therapeutics" of the 47th San Antonio Breast Cancer Symposium (SABCS), RemeGen Co. Ltd. ("RemeGen") (9995.HK,...
【2024 ASH】TransThera Announces the Phase I Study Results of TT-01488, a Novel Non-Covalent BTK Inhibitor, in Patients with Relapsed or Refractory B-cell Malignancies
NANJING, China and GAITHERSBURG, Md., Dec. 10, 2024 /PRNewswire/ -- TransThera Sciences (Nanjing), Inc. (the "TransThera"), a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing...
Live from ASH 2024 | First Dataset of Olverembatinib as Second-Line Therapy in Patients with Non-T315I-Mutant CP-CML Presented in Oral Report
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...
Live from ASH 2024 | 1.5-Year Follow-Up Data from a Global Study of Olverembatinib Reaffirms Potential in Overcoming Resistance/Intolerance to Ponatinib or Asciminib
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...
Arcfra Partner Day 2024 Successfully Held in Seoul
SEOUL, South Korea, Dec. 10, 2024 /PRNewswire/ -- Arcfra Pte. Ltd. (hereinafter referred to as "Arcfra," arcfra.com), a leading innovator in cloud infrastructure and full-stack solutions, hosted its first event for Korean partners on November 27th...
IASO Bio Presented Study Findings on the Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma with Equecabtagene Autoleucel(FUCASO) Myeloma at 2024 ASH
SHANGHAI and NANJING, China and SAN JOSE, Calif., Dec. 10, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies...
Adoption of an Exclusive Human Milk Diet Reduces Malnutrition Rates Among Vulnerable Premature Infants in Sydney Hospital
Preliminary Data From Observational Study Presented at Australian and New Zealand Neonatal Network Clinical Practice Improvement Conference ADELAIDE, Australia, Dec. 10, 2024 /PRNewswire/ -- Prolacta Bioscience®, the world's leading hospital...
Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH
BEIJING, SHANGHAI and BOSTON, Dec. 9, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company dedicated to developing therapies toward undruggable targets, today presented preliminary Phase I data of BET inhibitor JAB-8263...